Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebuild: Bydureon for Stent Endothelialisation in Type 2 Diabetes
NCT02621489Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Dec 2015
- Primary completion
- Aug 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Degree of non-covered stent struts at 12 weeks. Started Dec 2015; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02621489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621489.